Skip to main content

Advertisement

Fig. 6 | Journal of Experimental & Clinical Cancer Research

Fig. 6

From: The third-generation EGFR inhibitor AZD9291 overcomes primary resistance by continuously blocking ERK signaling in glioblastoma

Fig. 6

Combined with PD098059, a MEK/ERK inhibitor significantly increases the sensitivity of GBM cells to AZD9291. a Measurement of cell proliferation after treating with AZD9291 or PD098059 alone or their combinations by EdU incorporation assay. b and c Quantitative analysis of proliferative and invading cell numbers. The numbers of proliferative and invading cells were normalized to that of the control group. d U251 cells were incubated with AZD9291 or PD098059 alone or their combinations for 30 h. Cell invasive abilities were evaluated by transwell assay. Results were expressed as means ± SEM of three independent experiments. *P < 0.05 and **P < 0.01 compared with control group

Back to article page